Extension of the maturity date of the convertible notes
NEW YORK and SYDNEY, Australia, November 22, 2021 – Beroni Group (OTCQX: BNIGF;
NSX: BTG) (“Beroni” or the “Company”), a diversified international biopharmaceutical company focused on the research, development, innovation and commercialization of therapies and products for the treatment of global diseases, is pleased to ” announce that the maturity dates of the two convertible notes issued in May 2020 have been extended until May 2022.
In order to encourage the postponement of maturity dates, the Company has agreed to issue an additional 5% shares to noteholders upon conversion. Based on the new conditions, the maximum number of shares to be issued is 1,806,025 shares. All other terms of the convertible notes remain unchanged.
For more details on convertible notes, please refer to our announcement of May 27, 2020.
– ### –
About Beroni Group Limited
Beroni Group is an international biopharmaceutical company dedicated to the innovation and commercialization of drugs and therapies to fight various global diseases such as cancer and infectious diseases. Its diverse portfolio includes FDA / CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceuticals, and a development pipeline targeting oncology and cell therapies. Beroni is present in Australia, the United States, China and Japan. It is listed on the Australian National Stock Exchange and traded on the over-the-counter markets in the United States. To learn more about Beroni, please visit www.beronigroup.com.
For more information, please contact us at:
Telephone: +61 2 9159 1827
Beroni Group Ltd. published this content on 22 November 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on November 22, 2021 05:23:07 AM UTC.